Boundless Bio made a play to become the seventh US biotech to seek a public listing in 2024, ending a brief hiatus in IPO activity after a busy start to the year.
UK healthcare investor RYSE Asset Management has closed a new fund to support start-ups involved in digital health and care technologies, raising $50 million.
Avidity Biosciences has filed a private placement worth around $400 million, seeking a cash infusion to help advance its pipeline of clinical-stage candidates that combine
Southampton, UK-based start-up Curve Therapeutics has completed a £40.5 million ($51 million) in Series A financing for its drug discovery platform that enables drug scree
To mark upcoming Rare Disease Day, pharmaphorum asked a panel of experts to give their thoughts on the opportunities and challenges facing developers of rare disease therapies in 2024.
A team of scientists formerly working at Google DeepMind and Owkin have joined forces to create Bioptimus, a start-up that will apply generative artificial intelligence (G
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS